Good news is the addressable market was looked at by Lumos in October 2021 based on their Economic Evaluation of FebriDx.There is a reason why they managed to raise $63 million 2.5 years ago on IPO.Setbacks on FDA approval would no doubt have soured some investors. That is behind us now. Bring on agreements and sales!
(20min delay)